Evidence map›Paper›PMID 41545684›Full record

ArticleNPJ digital medicine2026

Towards interpretable prediction of recurrence risk in breast cancer using pathology foundation models.

Jakub R Kaczmarzyk, Sarah C Van Alsten, Alyssa J Cozzo, Rajarsi Gupta, Peter K Koo, Melissa A Troester, Katherine A Hoadley, Joel H Saltz

Abstract read
In one paragraph

Article in NPJ digital medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jakub R KaczmarzykDepartment of Biomedical Informatics, Stony Brook University, Stony Brook, NY, USA. jakub.kaczmarzyk@stonybrookmedicine.edu.
Sarah C Van AlstenLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Alyssa J CozzoLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Rajarsi GuptaDepartment of Biomedical Informatics, Stony Brook University, Stony Brook, NY, USA.
Peter K KooSimons Center for Quantitative Biology, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA.
Melissa A TroesterLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Katherine A HoadleyLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Joel H SaltzDepartment of Biomedical Informatics, Stony Brook University, Stony Brook, NY, USA.

Funding

Virology Research Program (Program 4)P30CA016086 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Deborah F. Tate · 1985 to 2026
$201.5M
Tissue Procurement & PathologyP50CA058223 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BENJAMIN CARLISLE CALHOUN · 1992 to 2026
$59.3M
MEDICAL SCIENTIST TRAINING PROGRAMT32GM008444 · NIGMS · STATE UNIVERSITY NEW YORK STONY BROOK · PI FROHMAN, MICHAEL A. · 1992 to 2024
$12.6M
TCIA Sustainment and Scalability - Platforms for Quantitative Imaging Informatics in Precision MedicineU24CA215109 · NCI · UNIV OF ARKANSAS FOR MED SCIS · PI BANERJEE, IMON, PRIOR, FRED WILLIAM · 2017 to 2021
$8.5M
Cancer Control Education ProgramT32CA057726 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Melissa B Gilkey, Melissa A. Troester · 2017 to 2026
$3.7M
P53, DNA Repair Imbalance, and Immune Response in Breast Cancer Mortality DisparitiesR01CA253450 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI KATHERINE A. HOADLEY, Melissa A. Troester · 2021 to 2026
$3.6M
Methods and Tools for Integrating Pathomics Data into Cancer RegistriesUH3CA225021 · NCI · STATE UNIVERSITY NEW YORK STONY BROOK · PI CLIFFORD, GARI DAVID, DURBIN, ERIC B. · 2020 to 2022
$1.9M
Specialized RNA analysis center for integrative genomic analysesU24CA264021 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI HAYES, DAVID N, HOADLEY, KATHERINE A. · 2021 to 2025
$1.7M
Breast Cancer Research Foundation HEI-23-003National Science Foundation IIS-2212046NCI NIH HHS 5UH3CA225021NCI NIH HHS P30 CA016086NCI NIH HHS P50 CA058223NCI NIH HHS R01 CA253450NCI NIH HHS R01CA253450NCI NIH HHS T32 CA057726NCI NIH HHS U24 CA215109NCI NIH HHS U24 CA264021NCI NIH HHS UH3 CA225021NIGMS NIH HHS T32 GM008444Susan G. Komen OGUNC1202U.S. Department of Defense HT94252310235
6 · The paper itself

Abstract

Transcriptomic assays such as the PAM50-based ROR-P score guide recurrence risk stratification in non-metastatic, ER-positive, HER2-negative breast cancer but are not universally accessible. Histopathology is routinely available and may offer a scalable alternative. We introduce MAKO, a benchmarking framework evaluating 12 pathology foundation models and two non-pathology baselines for predicting ROR-P scores from H&E-stained whole-slide images using attention-based multiple instance learning. Foundation models, large neural networks pre-trained on millions of pathology images and adaptable to diverse downstream tasks, were trained and validated on the Carolina Breast Cancer Study and externally tested on TCGA BRCA. Several foundation models outperformed baseline models across classification, regression, and survival tasks. CONCH achieved the highest ROC AUC, while H-optimus-0 and Virchow2 showed the top correlation with continuous ROR-P scores. All pathology models stratified CBCS participants by recurrence similarly to transcriptomic ROR-P. Using the HIPPO interpretability method, we found that tumor regions were necessary and sufficient for high-risk predictions, and we identified candidate tissue biomarkers of recurrence. These results highlight the promise of interpretable, histology-based risk models in precision oncology.

Identifiers

PMID41545684
PMCPMC12895011

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.